Department of Radiation Sciences, Diagnostic Radiology, Umeå University, SE-901 85, Umeå, Sweden.
Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden.
Cancer Imaging. 2019 Jul 23;19(1):52. doi: 10.1186/s40644-019-0237-1.
The role of hybrid imaging using F-fluoro-2-deoxy-D-glucose positron-emission tomography (FDG-PET), computed tomography (CT) and magnetic resonance imaging (MRI) to improve preoperative evaluation of rectal cancer is largely unknown. To investigate this, the RECTOPET (REctal Cancer Trial on PET/MRI/CT) study has been launched with the aim to assess staging and restaging of primary rectal cancer. This report presents the study workflow and the initial experiences of the impact of PET/CT on staging and management of the first patients included in the RECTOPET study.
This prospective cohort study, initiated in September 2016, is actively recruiting patients from Region Västerbotten in Sweden. This pilot study includes patients recruited and followed up until December 2017. All patients had a biopsy-verified rectal adenocarcinoma and underwent a minimum of one preoperative FDG-PET/CT and FDG-PET/MRI examination. These patients were referred to the colorectal cancer multidisciplinary team meeting at Umeå University Hospital. All available data were evaluated when making management recommendations. The clinical course was noted and changes consequent to PET imaging were described; surgical specimens underwent dedicated MRI for anatomical matching between imaging and histopathology.
Twenty-four patients have so far been included in the study. Four patients were deemed unresectable, while 19 patients underwent or were scheduled for surgery; one patient was enrolled in a watch-and-wait programme after restaging. Consequent to taking part in the study, two patients were upstaged to M1 disease: one patient was diagnosed with a solitary hepatic metastasis detected using PET/CT and underwent metastasectomy prior to rectal cancer surgery, while one patient with a small, but metabolically active, lung nodulus experienced no change of management. PET/MRI did not contribute to any recorded change in patient management.
The RECTOPET study investigating the role of PET/CT and PET/MRI for preoperative staging of primary rectal cancer patients will provide novel data that clarify the value of adding hybrid to conventional imaging, and the role of PET/CT versus PET/MRI.
NCT03846882 .
使用 F-氟代-2-脱氧-D-葡萄糖正电子发射断层扫描(FDG-PET)、计算机断层扫描(CT)和磁共振成像(MRI)进行混合成像以提高直肠癌术前评估的作用在很大程度上尚不清楚。为了研究这一点,启动了 RECTOPET(直肠癌症 PET/MRI/CT 试验)研究,旨在评估原发性直肠癌的分期和再分期。本报告介绍了该研究工作流程以及首批纳入 RECTOPET 研究的患者中 PET/CT 对分期和管理的初步影响。
这项前瞻性队列研究于 2016 年 9 月启动,正在瑞典韦斯特博滕地区积极招募患者。这项试点研究包括招募并随访至 2017 年 12 月的患者。所有患者均经活检证实为直肠腺癌,并至少接受了一次 FDG-PET/CT 和 FDG-PET/MRI 检查。这些患者被转介到于默奥大学医院的结直肠肿瘤多学科团队会议。在提出管理建议时,评估了所有可用数据。记录了临床过程,并描述了 PET 成像后的变化;手术标本进行了专门的 MRI 检查,以在影像学和组织病理学之间进行解剖匹配。
迄今为止,已有 24 名患者纳入该研究。4 名患者被认为不可切除,而 19 名患者接受或计划接受手术;1 名患者在重新分期后被纳入观察等待计划。由于参与了该研究,2 名患者分期升级为 M1 期:1 名患者在 PET/CT 检测到孤立性肝转移后接受了直肠癌手术前的转移切除术,而 1 名患者有一个小但代谢活跃的肺结节,其管理没有改变。PET/MRI 并未导致患者管理发生任何记录的变化。
正在调查 PET/CT 和 PET/MRI 对原发性直肠癌患者术前分期作用的 RECTOPET 研究将提供新数据,阐明混合成像相对于传统成像的优势,以及 PET/CT 与 PET/MRI 的作用。
NCT03846882。